日常实践中糖尿病黄斑水肿患者对玻璃体腔抗血管内皮生长因子治疗的依从性与坚持性
本研究纳入136例糖尿病黄斑水肿(DME)患者和109例年龄相关性黄斑变性(AMD)患者,评估玻璃体腔抗血管内皮生长因子治疗中的依从性与坚持性差异。结果显示46%的DME患者和22%的AMD患者至少有一次中断治疗,DME患者中断次数与视力变化显著相关(P=0.017)。作者认为需制定策略将DME患者与昂贵的玻璃体腔治疗绑定以改善结局。
要点
- 46%的DME患者和22%的AMD患者至少有一次治疗中断(延迟>100天)。
- 35%的DME患者和50%的AMD患者始终按计划就诊。
- DME患者中断次数与视力变化显著相关(P=0.017)。
核心结论
- AMD与DME患者在依从性和坚持性方面存在显著差异,且这影响结局。
- 作者认为需要制定策略将DME患者与昂贵的玻璃体腔治疗绑定以改善结局和疗效。
研究设计与样本
- 纳入136例DME患者(36%女性,65岁,22次就诊,13.9次注射,随访29.9个月)和109例AMD患者(59%女性,76岁,20次就诊,14.7次注射,随访22.3个月),最低随访12个月且至少5次注射。
- 评估错过预约(延迟>14天)和治疗中断(延迟>100天),所有延迟患者均被电话访谈以了解中断原因。
主要发现
- 46%的DME患者和22%的AMD患者至少有一次中断治疗。
- 35%的DME患者和50%的AMD患者始终按计划就诊。
- DME患者中断次数与视力变化显著相关(P=0.017)。
- 在60%的DME中断病例和38%的AMD中断病例中,视力比中断前更差。
- 最常见的中断原因是合并症(AMD 33%,DME 20%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We assessed differences in compliance and adherence (lateness of patients, visual acuity, reasons for abstaining) between patients with diabetic macular edema (DME) and patients with age-related macular degeneration (AMD), both under anti-vascular endothelial growth factor therapy. METHODS: We included 136 patients with DME (36% women, 65 years, 22 visits, 13.9 injections, and 29.9 months of follow-up) and 109 patients with AMD (59% women, 76 years, 20 visits, 14.7 injections, and 22.3 months of follow-up) (minimum follow-up of 12 months and at least 5 injections). We assessed missed appointments (lateness >14 days) and therapy break-offs (lateness >100 days). All delayed patients were called and interviewed for abstaining reasons. RESULTS: Forty-six percent of patients with DME and 22% of patients with AMD had at least one break-off. Thirty-five percent of patients with DME and 50% of patients with AMD were always on schedule. In patients with DME, there was significant correlation (P = 0.017) between the number of break-offs and change of visual acuity. In 60% DME and 38% AMD of break-off cases, visual acuity was worse than the before break-off. The most common reason for abstaining was comorbidities (33% AMD and 20% DME). CONCLUSION: There are significant differences between patients with AMD and DME regarding compliance and adherence, which also affects outcome. Strategies to tie patients with DME to costly intravitreal therapy need to be developed to improve outcomes and efficacy.
引用
- Weiss M, Sim DA, Herold T, et al. COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE. Retina. 2018. PMID: 29068914. doi:10.1097/IAE.0000000000001892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。